Impact Biomedical IBO
NYSE IBO
$3.80 -0.22 (-5.47%)
As of: Oct 22, 2026 · 3:58 PM EDT

Impact Biomedical (IBO) Gross Profit (2025 - 2026)

Updated

Impact Biomedical (IBO) reported Gross Profit of $2,000 for Q2 2026, down 66.7% from $6,000 a year earlier.

Analysis

Impact Biomedical (IBO) Gross Profit (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 Impact Biomedical 428.05 Mn 428.01 Mn 2,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2,000.00
Sep 30, 2025 17,000.00
Jun 30, 2025 6,000.00
API Access

Impact Biomedical Gross Profit API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-profit&ticker=IBO&period=max&api_key=YOUR_API_KEY